Earnings call transcript: Atomo Diagnostics posts 140% revenue jump in Q1 2026

Atomo Diagnostics reported a significant 140% increase in quarterly revenue to AUD 1.63 million in Q1 2026, driven by growth in its HIV franchise and a sharp rise in OEM sales. The company's HIV sales rose by 38% quarter-on-quarter to AUD 630,000, while OEM revenue jumped 450% to AUD 938,000, largely due to a partnership with Lumos Diagnostics.

However, the gross margin fell to 26% from 38% a year earlier, and the EBITDA loss widened to AUD 1.3 million, reflecting increased spending on regulatory work, product development, and leadership transition costs. Despite the strong revenue growth, Atomo's profitability remains under pressure, and the company is still in an investment phase aimed at building a larger product portfolio and improving operating leverage over time.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.